Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
Crossref DOI link: https://doi.org/10.1007/s10456-017-9555-8
Published Online: 2017-04-18
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rovithi, Maria
Verheul, Henk M. W.
License valid from 2017-04-18